Apolo V Acquisition Corp. Amendment to Definitive Agreement with TelyRx, Inc. and Rescheduling of Special Meeting of Shareholders

Executive Summary

• Apolo V Acquisition Corp. amended its Business Combination Agreement with TelyRx, revising the share consolidation ratio from 1 post‑share for every 45‑60 pre‑shares to a new range of 1 post‑share for every 20‑60 pre‑shares.
• The special shareholders’ meeting originally set for February 19, 2026 has been postponed; the new meeting date is March 5, 2026 (record date remains January 20, 2026).
• All other terms of the original Business Combination Agreement remain unchanged and in full force.

Key Details

• Amended Business Combination Agreement (BCA): Executed on February 19, 2026 among Apolo V, TelyRx, TelyRx Finco Inc., 1001474388 Ontario Inc., and Apolo V MergerCo Inc.
• Share Consolidation Ratio: Updated to a range of 1 post‑consolidation Apolo Share for every 20 to 60 pre‑consolidation Apolo Shares (previously 45–60).
• Special Meeting Rescheduling:
• Original meeting date: February 19, 2026.
• New meeting date: March 5, 2026 at 10:00 a.m. Toronto time, held in person at Wildeboer Dellelce LLP, Suite 800, 365 Bay Street, Toronto, Ontario.
• Record date for voting remains January 20, 2026.
• Meeting Materials: Amended disclosure materials will be filed and mailed to shareholders after any required regulatory approvals are obtained.
• Other Terms: No other provisions of the Business Combination Agreement have been altered; all remain in full effect.

Notable Quotes

(No executive quotes were provided in the release.)